A New Dosing Regimen for Nivolumab Plus Ipilimumab in Advanced Melanoma

The  CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.

Source: CancerNetwork - March 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news